Results 21 to 30 of about 216,260 (210)

Systematic review of efficacy, safety and pharmacokinetics of intravenous and intraventricular vancomycin for central nervous system infections

Frontiers in Pharmacology, 2022
Objective: The decision of vancomycin dosage for central nervous system (CNS) infections is still a challenge because its bactericidal nature in cerebrospinal fluid (CSF) has not been confirmed by human studies.
Shu-Ping Liu, Jing Xiao, Ya-Li Liu, Yue-E Wu, Hui Qi, Zhuang-Zhuang Wang, A-Dong Shen, A-Dong Shen, Gang Liu, Wei Zhao, Wei Zhao   +10 more
doaj   +1 more source

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital

International Journal of Pediatrics, 2018
Background. Vancomycin and piperacillin-tazobactam (PTZ) are commonly used as empirical therapy for patients with health care associated infections. Vancomycin has been recognized as a nephrotoxic agent and in a few cases in the literature PTZ has been ...
Mohammed Al Nuhait, Laila C. Abu Esba, Khalid Al Harbi, Meshary Al Meshary, Rami T. Bustami   +4 more
doaj   +1 more source

Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit

Frontiers in Pediatrics, 2022
ObjectiveTo explore the efficacy and safety of vancomycin as measured by pharmacokinetic/pharmacodynamic parameters in children with severe infection in the Pediatric Intensive Care Unit (PICU) and to determine the appropriate threshold for avoiding ...
Bo Zhou, Bo Zhou, Bo Zhou, Bo Zhou, Wenyi Xiong, Ke Bai, Ke Bai, Ke Bai, Ke Bai, Hongxing Dang, Hongxing Dang, Hongxing Dang, Hongxing Dang, Jing Li, Jing Li, Jing Li, Jing Li, Feng Xu, Feng Xu, Feng Xu, Feng Xu, Yue-qiang Fu, Yue-qiang Fu, Yue-qiang Fu, Yue-qiang Fu, Chengjun Liu, Chengjun Liu, Chengjun Liu, Chengjun Liu   +28 more
doaj   +1 more source

Risk of vancomycin-resistant enterococci bloodstream infection among patients colonized with vancomycin-resistant enterococci

Brazilian Journal of Infectious Diseases, 2015
Background: Vancomycin-resistant enterococci colonization has been reported to increase the risk of developing infections, including bloodstream infections.
Ahu Kara, İlker Devrim, Nuri Bayram, Nagehan Katipoğlu, Ezgi Kıran, Yeliz Oruç, Nevbahar Demiray, Hurşit Apa, Gamze Gülfidan   +8 more
doaj   +1 more source

The Nephrotoxicity of Vancomycin

Clinical pharmacology and therapy, 2017
Vancomycin use is often associated with nephrotoxicity. It remains uncertain, however, to what extent vancomycin is directly responsible, as numerous potential risk factors for acute kidney injury frequently coexist.
E. Filippone, W. Kraft, J. Farber
semanticscholar   +1 more source

Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia

Microbiology Spectrum
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures.
Ji Hyun Yun, Euijin Chang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sung-Han Kim, Sang-Ho Choi, Sang-Oh Lee, Yang Soo Kim   +9 more
doaj   +1 more source

Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort

Journal of Infection and Public Health, 2022
Background: Therapeutic drug monitoring (TDM) has proven effectiveness in maintaining efficacy and reducing toxicities associated with vancomycin. A trough level of (15–20 mg/L) for MRSA serious infections is recommended.
Juhaina Salim Al-Maqbali, Zahra Al Shukri, Nawf Al Sabahi, Intisar AL-Riyami, Abdullah M. Al Alawi   +4 more
doaj   +1 more source

Renaissance of Vancomycin: Approaches for Breaking Antibiotic-Resistance in Multidrug-Resistant Bacteria.

Canadian Journal of Microbiology (print), 2019
The emergence of multidrug-resistant bacteria demands innovations in the development of new antibiotics. For decades, the glycopeptide antibiotic vancomycin has been considered as the "last resort" treatment of severe infections caused by Gram-positive ...
E. Mühlberg, Florian Umstätter, C. Kleist, Cornelius Domhan, W. Mier, P. Uhl   +5 more
semanticscholar   +1 more source

Parenterally administered vancomycin in 29 dogs and 7 cats (2003‐2017)

Journal of Veterinary Internal Medicine, 2019
Background Vancomycin is commonly used to treat resistant bacterial infections in people. Reported adverse effects of vancomycin in people include acute kidney injury (AKI), neutropenia, and systemic allergic reaction.
Ian M. DeStefano, Annie S. Wayne, Elizabeth A. Rozanski, Jonathan M. Babyak   +3 more
doaj   +1 more source

The rise in vancomycin-resistant Enterococcus faecium in Germany: data from the German Antimicrobial Resistance Surveillance (ARS)

Antimicrobial Resistance and Infection Control, 2019
Due to limited therapeutic options, vancomycin-resistant Enterococcus faecium (VREF) is of great clinical significance. Recently, rising proportions of vancomycin resistance in enterococcal infections have been reported worldwide.
Robby Markwart, N. Willrich, S. Haller, I. Noll, Uwe Koppe, G. Werner, T. Eckmanns, A. Reuss   +7 more
semanticscholar   +1 more source